 Casava Sciences NASDAQ: SAVA stock rose 5 overnight in sympathy with Biogens NASDAQ: BIIB successful clinical trial of an Alzheimers drug called lecanemab. Lecanemab, developed with Eisai OTCMKTS: ESALY of Japan, showed a decline in symptoms among 1,795 patients with early Alzheimers, a brain disease impacting nearly one-third of Americans ages 85 and older. 